Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC AML Vaccine Following Chemotherapy Induced Remission
NCT01096602Phase 2Completed
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- May 2010
- Primary completion
- Dec 2023
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous dendritic cell-tumor fusion vaccine in acute myeloid leukemia (AML), sponsored by Beth Israel Deaconess Medical Center. Primary endpoint: Number of Participants With Adverse Events Associated With DC/AML Tumor Vaccine at 9 months. Started May 2010; status: completed.
02
Drugs
autologous dendritic cell-tumor fusion vaccine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01096602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01096602.